



Elidel[®] (pimecrolimus) – First-time generic

- On December 20, 2018, Oceanside Pharmaceuticals launched an authorized generic version of Bausch Health's [Elidel \(pimecrolimus\)](#) cream.
- Elidel is approved as second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and children 2 years of age and older, who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable.
- Elidel carries a boxed warning stating that long-term safety of topical calcineurin inhibitors has not been established.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.